**Conflict of interest**

Dr. Fujimoto received consultancy fees from Boehringer Ingelheim, Ono, and Bristol-Myers Squibb, and honoraria or research funding from Chugai, Ono, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and MSD.
